FSD Pharma is taking the lead on Psychedelic health careFSD Pharma is taking the lead on Psychedelic health care. The company will grow and add to its collection of proprietary molecules with exclusive worldwide rights with the acquisition of Lucid Psycheceuticals. Demand for these treatments will increase as the benefits become more well-known in the mainstream. They are an attractive option for investors as treatments are rolled out on a significantly larger scale.